Sarilumab use in severe SARS-CoV-2 pneumonia.
Inflammation
Sarilumab
Severe sars-cov-2 pneumonia
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
23
06
2020
revised:
03
09
2020
accepted:
07
09
2020
pubmed:
13
10
2020
medline:
13
10
2020
entrez:
12
10
2020
Statut:
ppublish
Résumé
Interleukin-6 signal blockade showed preliminary beneficial effects in treating inflammatory response against SARS-CoV-2 leading to severe respiratory distress. Herein we describe the outcomes of off-label intravenous use of Sarilumab in severe SARS-CoV-2-related pneumonia. 53 patients with SARS-CoV-2 severe pneumonia received intravenous Sarilumab; pulmonary function improvement or Intensive Care Unit (ICU) admission rate in medical wards, live discharge rate in ICU treated patients and safety profile were recorded. Sarilumab 400 mg was administered intravenously on day 1, with eventual additional infusion based on clinical judgement, and patients were followed for at least 14 days, unless previously discharged or dead. Of the 53 SARS-CoV-2 IL-6R inhibition appears to be a potential treatment strategy for severe SARS-CoV-2 pneumonia and intravenous Sarilumab seems a promising treatment approach showing, in the short term, an important clinical outcome and good safety.
Sections du résumé
BACKGROUND
BACKGROUND
Interleukin-6 signal blockade showed preliminary beneficial effects in treating inflammatory response against SARS-CoV-2 leading to severe respiratory distress. Herein we describe the outcomes of off-label intravenous use of Sarilumab in severe SARS-CoV-2-related pneumonia.
METHODS
METHODS
53 patients with SARS-CoV-2 severe pneumonia received intravenous Sarilumab; pulmonary function improvement or Intensive Care Unit (ICU) admission rate in medical wards, live discharge rate in ICU treated patients and safety profile were recorded. Sarilumab 400 mg was administered intravenously on day 1, with eventual additional infusion based on clinical judgement, and patients were followed for at least 14 days, unless previously discharged or dead.
FINDINGS
RESULTS
Of the 53 SARS-CoV-2
INTERPRETATION
CONCLUSIONS
IL-6R inhibition appears to be a potential treatment strategy for severe SARS-CoV-2 pneumonia and intravenous Sarilumab seems a promising treatment approach showing, in the short term, an important clinical outcome and good safety.
Identifiants
pubmed: 33043284
doi: 10.1016/j.eclinm.2020.100553
pii: S2589-5370(20)30297-2
pmc: PMC7531933
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100553Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
All authors declare no conflict of interest with the submitted manuscript.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
Ann Surg. 1992 Apr;215(4):356-62
pubmed: 1558416
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Ann Rheum Dis. 2021 Jun;80(6):e91
pubmed: 32632032
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
BMJ. 2020 Feb 28;368:bmj.m799
pubmed: 32111645
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Ann Rheum Dis. 2017 May;76(5):840-847
pubmed: 27856432
BMJ. 2020 Feb 19;368:m606
pubmed: 32075786
Clin Infect Dis. 2020 Nov 5;71(8):1937-1942
pubmed: 32301997
Eur J Clin Invest. 2020 Sep;50(9):e13342
pubmed: 32645207
Am J Respir Crit Care Med. 2020 May 15;201(10):P19-P20
pubmed: 32223716
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
Ann Rheum Dis. 2020 Oct;79(10):1277-1285
pubmed: 32620597
Crit Care Med. 2020 Jun;48(6):e440-e469
pubmed: 32224769